Case studies in therapeutics: Warfarin resistance and inefficacy in a man with recurrent thromboembolism, and anticoagulant-associated priapism

British Journal of Clinical Pharmacology

Volumn 46, Issue 4, 1998, Pages 343-346

  Routledge, P A ^a   Shetty, H G M ^a   White, J P ^a   Collins, P ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BUTYROPHENONE; CANNABIS; CHARCOAL; CHLORPROMAZINE; COLESTIPOL; COLESTYRAMINE; DIPHENHYDRAMINE; DROPERIDOL; ESTROGEN; FLUPHENAZINE; GRISEOFULVIN; HALOPERIDOL; HEPARIN; HYDRALAZINE; LABETALOL; LISINOPRIL; MERCAPTOPURINE; METARAMINOL; PHENELZINE; PHENOTHIAZINE; PHENOXYBENZAMINE; PRAZOSIN; PROMAZINE; THIORIDAZINE; TRAZODONE; UNINDEXED DRUG; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; HUMAN; HYPERTENSION; INTRACAVERNOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIAPISM; PRIORITY JOURNAL; THROMBOEMBOLISM; THROMBOPHLEBITIS;

EID: 0031683093     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.t01-1-00796.x     Document Type: Article

References (27)

1. Routledge PA, Shetty HGM. Pharmacology of anticoagulants. In Current issues in heart valve disease: thrombosis, embolism and bleeding, eds Butchart EG, Bodnar E. pp. 263-276, ICR Publishers, London (1992).
2. Nikkila EA, Pelkonen R. Serum lipid-reducing agents and anticoagulant requirements. Lancet 1963; i: 332.
3. Robinson A, Liau FAO, Routledge PA, Backhouse G, Spragg BP, Bentley DP. Lipids and warfarin requirements. Thromb Haemost 1990; 63: 148-149.
4. O'Reilly RA, Aggeler PM, Hoag S, Leong LS, Kropatkin ML. Hereditary transmission of exceptional resistance to coumarin anticoagulant drugs. N Engl J Med 1964; 271: 809-813.
5. O'Reilly RA. The second reported kindred with hereditary resistance to oral anticoagulant drugs. N Engl J Med 1970; 282: 1448-1451.
6. Bentley DP, Backhouse G, Hutchings A, Haddon RL, Spragg BP, Routledge PA. Investigation of patients with abnormal response to warfarin. Br J Clin Pharmacol 1986; 22: 37-41.
7. Piccioli A, Prandoni P, Ewenstein BM, Goldhaber SZ. Cancer and venous thromboembolism. Am Heart J 1996; 132: 850-855.
8. Banos JE, Bosch F, Farre M. Drug-induced priapism: Its aetiology, incidence and treatment. Med Toxicol 1989; 4: 46-58.
9. Duggan MI, Morgan C. Heparin: A cause of priapism? Southern Med J 1970; 63: 1131-1134.
10. Granger CB, Miller JM, Bovill EG, et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995; 91: 1929-1935.
11. Smith AJ, Holt RE, Fitzpatrick JB, et al. Transient thrombotic state after abrupt discontinuation of heparin in percutaneous coronary angioplasty. Am Heart J 1996; 131: 434-439.
12. Port FK, Fiegel P, Hecking E, Kohler H, Distler. Priapism during regular haemodialysis. Lancet 1974; ii: 1287-1288.
13. Burke BJ, Scott GL, Smith PJB, Wakerley GR. Heparin-associated pnapism. Postgrad Med J 1983; 59: 332-333.
14. Thomson C, Forbes CD, Prentice CRM. The potentiation of platelet aggregation and adhesion by heparin in vitro and in vivo. Clin Sci Mol Med 1973; 45: 485-488.
15. Salzman EW, Rosenberg RD, Smith MH, Lindon, JN, Favreau L. Effects of heparin and hepann fractions on platelet aggregation. J Clin Invest 1980; 65: 64-73.
16. Eadie DG, Brock TP. Corpus saphenous by-pass in the treatment of priapism. Br J Surg 1970; 57: 172-174.
17. Grace DA, Winter CC. Priapism: an appraisal of management of twenty three patients. J Urol 1968; 99: 301-310.
18. Klein LA, Hall RL, Smith RB. Surgical treatment of priapism: with a note on heparin-induced priapism. J Urol 1972; 108: 104-106.
19. Kulmala RV, Lehtonen TA, Tammela TL. Preservation of potency after treatment for priapism. Scand J Urol Nephrol 1996; 30: 313-316.
20. Donati MB. Cancer and thrombosis: from Phlegmasia alba dolens to transgenic mice. Thromb Haemost 1995; 74: 278-281.
21. Prandoni P, Lensing AW, Buller HR, et al. Deep vein thrombosis and the incidence of subsequent cancer. N Engl J Med 1992; 327: 1128-1133.
22. Agnelli G. Venous thromboembolism and cancer: a two-way association. Thromb Haemost 1997; 78: 117-120.
23. Monreal M, Lafoz E, Casals A, et al Occult cancer in patients with deep vein thrombosis. A systematic approach. Cancer 1991; 67: 541-545.
24. Cohen JR, Tenenbaum N, Citron M. Greenfield filter as primary therapy for deep vein thrombosis and/or pulmonary embolism in patients with cancer. Surgery 1991; 109: 12-15.
25. Cohen JR, Grella L, Citron M. Greenfield filter instead of heparin as primary treatment for deep venous thrombosis or pulmonary embolism in patieints with cancer. Cancer 1992; 70: 1993-1996.
26. Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886-889.
27. Prandoni P. Antithrombotic strategies in patients with cancer. Thromb Haemost 1997; 78: 141-144.